恩替卡韦联合水飞蓟宾治疗乙肝合并非酒精性脂肪肝患者的临床疗效及对患者肝功能的影响

doi:10.3969/j.issn.1671-7171.2024.08.028

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1166 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨恩替卡韦联合水飞蓟宾治疗乙型病毒性肝炎(CHB)合并非酒精性脂肪肝(NAFLD)患者的临床疗效及对患者肝功能的影响。【方法】选取2021年6月至2023年1月本院收治的104例CHB合并NAFLD患者,根据治疗方法将其分为对照组(在常规治疗的基础上给予恩替卡韦治疗)和观察组(在对照组的基础上给予水飞蓟宾治疗),每组52例。比较两组临床效果、肝功能[丙转氨酶(ALT)、谷草转氨酶(AST)、肿瘤标志物甲胎蛋白(AFP)]、肝纤维化指标[层粘连蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)、Ⅳ型胶原(Ⅳ-C)、透明质酸(HA)]、炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、核因子-κB(NF-κB)]。【结果】观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组ALT、AST、AFP低于治疗前,且观察组低于对照组(P<0.05);两组血清LN、PC-Ⅲ、Ⅳ-C、HA水平低于治疗前,且观察组低于对照组(P<0.05);两组血清IL-6、TNF-α、NF-κB水平低于治疗前,且观察组低于对照组(P<0.05)。【结论】恩替卡韦联合水飞蓟宾治疗CHB合并NAFLD患者可改善肝功能,减轻机体炎症反应,缓解肝纤维化进展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	翟云峰
	李秀荣

关键词 ：非酒精性脂肪性肝病, 水飞蓟素, 治疗结果, 肝功能试验

Abstract：【Objectives】To investigate the clinical efficacy of entecavir combined with silibinin in the treatment of patients with viral hepatitis B (CHB) complicated with non-alcoholic fatty liver disease (NAFLD) and its impact on liver function. 【Methods】A total of 104 patients with CHB and NAFLD admitted to our hospital from June 2021 to January 2023 were selected and divided into the control group (treated with entecavir in addition to conventional treatment) and the observation group (treated with silibinin in addition to conventional treatment) according to the treatment method, with 52 patients in each group. Two groups were compared in terms of clinical efficacy, liver function [alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor marker alpha fetoprotein (AFP)], liver fibrosis indicators [laminin (LN), type Ⅲ procollagen (PC-Ⅲ), type Ⅳ collagen (Ⅳ-C), hyaluronic acid (HA)], inflammatory factors [interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B (NF-κB)]. 【Results】The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, ALT, AST, and AFP levels in both groups were lower than before treatment, and the observation group was lower than the control group (P<0.05); The serum levels of LN, PC-Ⅲ,Ⅳ-C, and HA in both groups were lower than before treatment, and the observation group was lower than the control group (P<0.05); The serum levels of IL-6, TNF-α, and NF-κB in both groups were lower than before treatment, and the observation group was lower than the control group (P<0.05).【Conclusion】 The combination of entecavir and silibinin in the treatment of CHB patients with NAFLD can improve liver function, reduce inflammatory response, and alleviate the progression of liver fibrosis.

Key words： Non-alcoholic Fatty Liver Disease Silybin Treatment Outcome Liver Function Tests

收稿日期: 2023-09-14

中图分类号:

R575

引用本文:

翟云峰, 李秀荣. 恩替卡韦联合水飞蓟宾治疗乙肝合并非酒精性脂肪肝患者的临床疗效及对患者肝功能的影响[J]. 医学临床研究, 2024, 41(8): 1216-1218.
ZHAI Yunfeng, LI Xiurong. Clinical Efficacy of Entecavir Combined with Silibinin in the Treatment of Hepatitis B Patients with Non-alcoholic Fatty Liver Disease and its Influence on Liver Function. JOURNAL OF CLINICAL RESEARCH, 2024, 41(8): 1216-1218.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.08.028 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I8/1216

[1] KAYESH M E H,KOHARA M,TSUKIYAMA-KOHARA K.Toll-like receptor response to hepatitis B virus infection and potential of TLR agonists as immunomodulators for treating chronic hepatitis B: an overview[J].Int J Mol Sci,2021,22(19):10462.
[2] TONG X,SONG Y,YIN S,et al.Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease[J].Chin Med J (Engl),2022,135(14):1653-1663.
[3] 贾婷,李俊义,张秀灵,等.恩替卡韦联合聚乙二醇干扰素α-2b治疗低水平血清HBsAg阳性的慢性乙型肝炎患者疗效研究[J].实用肝脏病杂志,2022,25(4):488-491.
[4] 聂璐,苏成霞.穴位埋线联合水飞蓟宾对非酒精性脂肪性肝炎患者免疫失衡和炎症因子的影响[J].现代中西医结合杂志,2022,31(15):2138-2141.
[5] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].临床肝胆病杂志,2019,35(12):2648-2669.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].中华肝脏病杂志,2018,26(3):195-203.
[7] 马丽,李淑敏,李洁.慢性乙肝患者血清甲状腺激素、HBV-DNA及血清钙的表达与病情严重程度的相关性[J].现代消化及介入诊疗,2021,26(11):1441-1444.
[8] 龙爽爽,姜伟,董亚楠,等.自拟消癖化痰颗粒联合水飞蓟宾胶囊治疗非酒精性脂肪性肝炎(痰湿内阻证)的临床研究[J].中医药导报,2022,28(2):66-70.
[9] 张圣江,周杨,柯淑红,等.五苓散加味联合水飞蓟宾对痰瘀互结型非酒精性脂肪性肝病患者肝功能、血脂和Th17/Treg平衡状态的影响[J].中西医结合肝病杂志,2021,31(8):691.
[10] 温庆杰.恩替卡韦联合水飞蓟宾药物治疗乙型病毒性肝炎肝硬化效果分析[J].国际感染病学(电子版),2020,9(1):130-131.
[11] 刘皎皎,杨跃青,叶苗清,等.消脂护肝汤联合水飞蓟宾对非酒精性脂肪肝患者糖脂代谢水平及肝功能的影响[J].世界中西医结合杂志,2021,16(7):1177-1180.
[12] 刘俊平,郭新忠,李晓敏,等.水飞蓟宾胶囊对慢性HBV感染患者肝纤维化Wnt/β-catenin信号通路的影响[J].中华医院感染学杂志,2022,32(3):336-340.
[13] 叶苗青,薛敬东,李粉萍,等.化脂复肝颗粒对非酒精性脂肪肝TLR4/NF-κB通路及脂肪铁死亡的调控及机制研究[J].现代中西医结合杂志,2021,30(30):3307-3312.
[14] 苏正昌.恩替卡韦联合水飞蓟宾治疗乙肝肝硬化效果观察及对肝纤维化和微炎症状态的影响[J].白求恩医学杂志,2018,16(1):21-23.